Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Available × INDUSTRY × Oncogenic osteomalacia × Clear all

Status

Completed 3 Available 1 Active not recruiting 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 7 Neoplasms 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Multiple Myeloma 5 Sarcoma 4 Prostatic Neoplasms 4 Pancreatic Neoplasms 4 Melanoma 4 Lymphoma, Large B-Cell, Diffuse 4 Recurrence 3 Ovarian Neoplasms 3 Leukemia, Myeloid, Acute 3 Glioblastoma 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Primary Myelofibrosis 2 Non-Muscle Invasive Bladder Neoplasms 2 Neuroblastoma 2 Neoplasm Metastasis 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Follicular 2 Head and Neck Neoplasms 2 Gastrointestinal Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Transitional Cell 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Brain Neoplasms 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03775187 2025-03-05

Expanded Access to Burosumab

Kyowa Kirin Co., Ltd.

Oncogenic osteomalacia, Familial Hypophosphatemic Rickets

Data powered by HemOnc (CC BY 4.0) Colophon ⚡